Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01883544 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects | PHASE1 | COMPLETED | 16 | — | — | Jun 1, 2013 | Jan 1, 2014 | Mar 31, 2014 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| ALXN1007 | EXPERIMENTAL | Infusion of ALXN1007 |
| placebo | PLACEBO_COMPARATOR | Infusion placebo |
| Name | Type | Description |
|---|---|---|
| ALXN1007 | DRUG | - |
Inclusion Criteria: Healthy male or female (not of childbearing potential) subjects ≥25 and ≤55 years old. 2\. QTcF ≤450 msec and ≤470 for females. 3. Willing and able to give written informed consent and comply with the study visit schedule. 4\. Male subject and his female spouse/partner who is ...